Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

TCT 2021 | FAME 3: Surprises in a Long-Awaited Study

Angioplasty could not reach non-inferiority to surgery to treat patients with three-vessel lesions.

FAME 3: Sorpresas en un estudio largamente esperado

In this head-to-head study of both revascularization strategies in patients with three-vessel coronary disease, fractional flow reserve (FFR)-guided angioplasty could not reach the performance of myocardial revascularization surgery in relation to a composite of adverse events.

The FAME 3 study was presented during the TCT 2021 scientific sessions, and it was simultaneously published in NEJM. Patients treated with FFR-guided angioplasty had higher all-cause mortality, infarction, stroke, or repeat revascularization rates compared with surgery.

When analyzed individually, none of the composite endpoints indicated a clear advantage in favor of either strategy. Only stroke events were numerically higher using angioplasty: a non-significant outcome that challenges previous evidence.

While patients with a Syntax score below 23 found benefit in angioplasty, this subgroup analysis can only generate hypothesis.

Results account for only one year of follow-up, but—since repeat revascularization is included among the endpoints—results are only bound to gain consistency over time.

Read also: Atrial Fibrillation and Dementia: Which Anticoagulant Agent Presents the Lowest Risk?

FAME 3 included 1500 patients with three-vessel coronary disease randomized to FFR-guided angioplasty or surgery. All patients had angina or evidence of ischemia, and all were good candidates for either strategy. Left main coronary artery lesion was an exclusion criteria for this study.

Researchers used the classic FFR threshold (0.8) and zotarolimus-releasing stent Resolute Integrity.

After a year of follow-up, the rate for the composite endpoint was 10.6% for angioplasty and 6.9% for surgery (hazard ratio: 1.5; 95% confidence interval: 1.1 to 2.2).

Read also: AFIRE Trial: Atrial Fibrillation and PCI. What is the Ideal Therapy?

The risk for major bleeding, arrhythmia, and acute kidney injury was lower with angioplasty.

Considering the group with low Syntax score, the result is 5.5% for angioplasty vs. 8.6% for surgery—but we have previously mentioned the limitations of this analysis.

Original Title: Fractional flow reserve-guided PCI as compared with coronary bypass surgery.

Reference: Fearon WF et al. N Engl J Med 2021; Epub ahead of print y presentado simultáneamente en TCT 2021. doi: 10.1056/NEJMoa2112299.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...